NCT02612844View on ClinicalTrials.gov

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

NNC0143-0406

Subject will receive one single dose only Subcutanesously (s.c., under the skin)

DRUG

insulin aspart

Subject will receive one single dose only. Subcutanesously (s.c., under the skin)

Trial Locations (1)

8010

Novo Nordisk Investigational Site, Graz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT02612844 - A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes | Biotech Hunter | Biotech Hunter